CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant ...
In a 2025 JAMA Network Open invited commentary, Melina E. Marmarelis, MD, MSCE, and Lauren Reed-Guy, MD, both of the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Given the importance of pathologic examination in patients with resectable NSCLC, we do not consider ORR per RECIST to be a clinically relevant end point when pathologic stage and response are ...
Use of neoadjuvant or perioperative immunotherapy in combination with chemotherapy has proven effective for some patients with non-small cell lung cancer (NSCLC), but its role in patients with EGFR- ...
NeoADAURA: Can We Afford to Overlook Objective Response Rates? The following represents disclosure information provided by author of this manuscript. All relationships are considered compensated ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...
FREMONT, Calif., September 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results